This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.
Safety Profile1
In clinical studies, the most commonly occurring adverse events (≥20%) of any grade in patients receiving:
*Includes ‘neutropenia’ and ‘neutrophil count decreased’.
The most frequently reported serious adverse reactions (≥2%) in patients receiving:
†Includes multiple preferred terms. These included: pneumonia, bronchitis, bronchopulmonary aspergillosis, cellulitis, Clostridium colitis, erysipelas, gastroenteritis, gastrointestinal infection, infection, influenza, cytomegaloviral pneumonia, septic shock, tonsillitis; patients may have had more than one adverse event.
Please refer to the relevant SmPCs (available at www.medicines.org.uk) for further information
FD, Fixed-duration; SmPC, Summary of Product Characteristics; VEN+I, VENCLYXTO + ibrutinib; VEN+O, VENCLYXTO + obinutuzumab; VEN+R, VENCLYXTO +rituximab.
References
- VENCLYXTO Summary of Product Characteristics.
- Kater AP et al. NEJM Evid. 2022;1(7) doi: 10.1056/EVIDoa2200006 (and suppl.).
- Tam CS et al. Blood. 2022; 139(22): 3278-89 (and suppl.).
UK-VNCCLL-250053. Date of preparation: March 2025.
You are advised to read the Prescribing Information and Summary of Product Characteristics to evaluate patient suitability for VENCLYXTO.
VENCLYXTO PRESCRIBING INFORMATION
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
